Affiliation: University of Pittsburgh
- Role of the microenvironment in multiple myeloma bone diseaseAlissa Huston
University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
Future Oncol 2:371-8. 2006....
- Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaLanie K Francis
University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
Clin Cancer Res 12:6826-35. 2006..Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells...
- Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myelomaAlissa Huston
Exp Hematol 34:1616. 2006
- Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironmentAlissa Huston
James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
Clin Cancer Res 14:865-74. 2008....
- Involvement of hepcidin in the anemia of multiple myelomaSanjai Sharma
West Los Angeles VA University of California Los Angeles Medical Center, Los Angeles, CA 90073, USA
Clin Cancer Res 14:3262-7. 2008..Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma...